Dosing Schedule For Solvay’s Pulzium Will Be Addressed During Cardio-Renal Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Cardiovascular and Renal Drugs Advisory Committee also will weigh whether tedisamil should be approved with risk management plan proposed by Solvay.